Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: Big Pharma And Big Biotech Are The New Black

This article was originally published in Scrip

Executive Summary

Unlike the temporary blips of the last year when pharmacy benefit manager Express Scripts Holding Corp. went to war with Gilead Sciences, Inc. on drug pricing, or Federal Reserve chair Yellen warned on the frothy valuations of early-stage biotech companies, this time it is different. Firstly it has lasted longer than previous pull-backs, secondly, like the stock market retrenchment that followed the tragedies of September 11 2001, there is no direct connection with life science stocks, and thirdly, the supposedly unrelated initiating factor – China's slowing economic growth and the bursting of its stock market bubble – was in temporary remission on Thursday and Friday last week but life science stocks still traded off on both days. This time I am afraid that the market means it and as generalists continue to rotate out of life sciences, there are reasons to believe that bigger is going to be better as the investors who are left focus on tangible investment attributes for a change.

Advertisement

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC029689

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel